| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 36 |
| 1 | NIVOLUMAB | 35 |
| 2 | IPILIMUMAB | 24 |
| 3 | CARBOPLATIN | 7 |
| 4 | ATEZOLIZUMAB | 6 |
| 5 | PANTOPRAZOLE | 6 |
| 6 | ANTI ITCH | 4 |
| 7 | ANTI-ITCH | 4 |
| 8 | ANTI-ITCH CREAM | 4 |
| 9 | ANTI-PRURITIC | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DOSTARLIMAB | 2 | 0.0008 |
| 1 | ALDESLEUKIN | 1 | 0.0008 |
| 2 | GINKGO BILOBA | 1 | 0.0007 |
| 3 | CIDOFOVIR ANHYDROUS | 1 | 0.0007 |
| 4 | FLURBIPROFEN | 1 | 0.0007 |
| 5 | IPILIMUMAB | 24 | 0.0005 |
| 6 | AVELUMAB | 2 | 0.0005 |
| 7 | OSILODROSTAT | 1 | 0.0005 |
| 8 | TREMELIMUMAB | 2 | 0.0005 |
| 9 | NIVOLUMAB | 35 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 72 | 0.0007 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 24 | 0.0005 |
| 3 | Phosphate Binder [EPC] | 1 | 0.0003 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 5 | Thyroid Hormone Synthesis Inhibitor [EPC] | 1 | 0.0001 |
| 6 | CD30-directed Immunoconjugate [EPC] | 1 | 0.0001 |
| 7 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 2 | 0.0001 |
| 8 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 2 | 0.0001 |
| 9 | Interleukin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |